Ultragenyx Pharmaceutical Inc. (RARE) Financials
RARE Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 1.3 billion | 1.2 billion |
2023-12-31 | 1.5 billion | 1.2 billion |
2023-09-30 | 1.2 billion | 1.2 billion |
2023-06-30 | 1.3 billion | 1.2 billion |
RARE Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | -203.9 million | ? |
2023-12-31 | -85.5 million | 33.7 million |
2023-09-30 | -121.6 million | 34.9 million |
2023-06-30 | -132.6 million | 34.7 million |
RARE Net Income
No data available :(
RARE Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 418.4 million | - | - |
2023-12-31 | 777.1 million | - | 43.2 million |
2023-09-30 | 524.2 million | - | 46.6 million |
2023-06-30 | 552.0 million | - | 25.7 million |
RARE Shares Outstanding
RARE Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 13.2 million | 169.6 million | - | - |
2023-12-31 | 1.6 million | 160.6 million | 76.8 million | - |
2023-09-30 | 3.7 million | 157.2 million | 74.9 million | - |
2023-06-30 | 16.4 million | 164.9 million | 81.4 million | - |
RARE Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 108.8 million | 26.4 million |
2023-12-31 | 127.4 million | 12.1 million |
2023-09-30 | 98.1 million | 11.0 million |
2023-06-30 | 108.3 million | 9.9 million |
RARE
Price: $43.01
52 week price:
Earnings Per Share: -8.25 USD
P/E Ratio: -5.24
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 449700
Ebitda: -96.8 millionMarket Capitalization: 3.6 billion